Novabridge Biosciences (NASDAQ:NBP) Stock: Insider Mark Arnold Hagler Purchases 184,000 Shares

Novabridge Biosciences (NASDAQ:NBP – Get Free Report) insider Mark Arnold Hagler acquired 184,000 shares of the stock in a transaction dated Wednesday, November 18th. The stock was bought at an average price of $0.38 per share, with a total value of $69,920.00. Following the purchase, the insider directly owned 460,000 shares in the company, valued at $174,800. This represents a 66.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Mark Arnold Hagler also recently made the following trade(s):

  • On Tuesday, November 17th, Mark Arnold Hagler bought 46,000 shares of Novabridge Biosciences stock. The shares were bought at an average cost of $0.34 per share, for a total transaction of $15,640.00.

Novabridge Biosciences Stock Down 2.6%

NASDAQ:NBP traded down $0.02 during trading hours on Thursday, reaching $0.88. The company had a trading volume of 213,480 shares, compared to its average volume of 681,761. The firm has a market cap of $102.06 million, a price-to-earnings ratio of -2.44 and a beta of 1.70. The business’s 50-day simple moving average is $1.27 and its two-hundred day simple moving average is $1.98. Novabridge Biosciences has a twelve month low of $0.75 and a twelve month high of $5.19.

Novabridge Biosciences (NASDAQ:NBP – Get Free Report) last announced its quarterly earnings data on Thursday, August 20th. The company reported ($0.16) earnings per share for the quarter. As a group, equities analysts predict that Novabridge Biosciences will post -0.54 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Novabridge Biosciences in a report on Thursday, August 27th. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Novabridge Biosciences in a report on Thursday, August 20th. Finally, Wall Street Zen raised Novabridge Biosciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 15th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $9.00.

Get Our Latest Stock Analysis on NBP

About Novabridge Biosciences

(Get Free Report)

Novabridge Biosciences (NASDAQ: NBP) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel biologic medicines, primarily for the treatment of cancer. Its research and development activities center on immunotherapies designed to activate the immune system or target specific proteins associated with tumor growth and survival. The company’s pipeline has included investigational antibody-based therapies such as givastomig, a bispecific antibody designed to target Claudin 18.2 and stimulate an immune response through 4-1BB, as well as other programs directed at tumor-associated and immune-regulatory targets.

Featured Articles

Insider Buying and Selling by Quarter for Novabridge Biosciences (NASDAQ:NBP)

Receive News & Ratings for Novabridge Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novabridge Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.